Two clinical trials of an off-the-shelf CAR-T cancer therapy from Cellectis (CLLS) have been placed on clinical hold following the death of a patient caused by a severe toxic reaction to the treatment.
Cellectis’ stock price is down 30 percent to $22.79 in early Tuesday trading. The biotech company, with operations in Paris and New York, announced the FDA clinical hold on Sunday night.
About the Author Reprints
